Analysts on Wall Street project that Thermo Fisher Scientific (TMO) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year. Revenues are projected to reach $10.65 billion, increasing 1% from the same quarter last year.The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial pro ...

Wall Street analysts expect Alphabet (GOOGL) to post quarterly earnings of $2.14 per share in its upcoming report, which indicates a year-over-year increase of 13.2%. Revenues are expected to be $79.25 billion, up 11.1% from the year-ago quarter.The current level reflects an upward revision of 1.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company ...

Wall Street analysts expect Freeport-McMoRan (FCX) to post quarterly earnings of $0.46 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $7.12 billion, up 7.5% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 11% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earning ...

In its upcoming report, Tesla (TSLA) is predicted by Wall Street analysts to post quarterly earnings of $0.40 per share, reflecting a decline of 23.1% compared to the same period last year. Revenues are forecasted to be $22.48 billion, representing a year-over-year decrease of 11.9%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this ...

Alphabet (GOOGL) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this internet search leader have returned +5.9%, compared to the Zacks S&P 500 composite's +5.4% change. During this period, the Zacks Internet - Services industry, which Alphabet falls in, has gained 4.9%. The key question now is: What could be the stock's future direction?While media relea ...

Townsquare Media (TSQ) shares ended the last trading session 6.9% higher at $9.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.5% gain over the past four weeks.Townsquare is benefiting from the expansion of its programmatic digital advertising services, growth in its subscription-based marketing platform, and partnerships with local media companies across underserved markets.This operator of radio stations i ...

One stock that might be an intriguing choice for investors right now is Amazon.com, Inc. (AMZN) . This is because this security in the Internet - Commerce space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Inter ...

Schlumberger (SLB) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.37%. A quarter ago, it was expected that this world's largest oilfield services company would post earnings of $0.74 per share when it actually produced earnings of $0.72, delivering a surprise of -2.7%.Over the las ...

Core Viewpoint - Comerica Incorporated (CMA) reported quarterly earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, but down from $1.53 per share a year ago, indicating an earnings surprise of +15.45% [1][2] Financial Performance - The company posted revenues of $849 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.51% and up from $824 million year-over-year [2] - Over the last four quarters, Comerica has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance and Outlook - Comerica shares have increased by approximately 0.9% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's current consensus EPS estimate for the upcoming quarter is $1.32 on revenues of $856.2 million, and for the current fiscal year, it is $5.08 on revenues of $3.39 billion [7] Industry Context - The Zacks Industry Rank for Banks - Major Regional is currently in the top 7% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Company Overview - Legend Biotech Corporation's shares increased by 6% to close at $42.13, with a notable trading volume compared to normal sessions, and a total gain of 13.9% over the past four weeks [1][2] Product Performance - The rise in stock price is attributed to investor optimism regarding the strong sales of Carvykti, a therapy for relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson [2] Financial Expectations - The company is projected to report a quarterly loss of $0.18 per share, reflecting a year-over-year decline of 260%, while revenues are expected to reach $233.67 million, marking a 25.3% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 4.1% higher in the last 30 days, indicating a potential for price appreciation [4] Industry Context - Legend Biotech is categorized within the Zacks Medical - Biomedical and Genetics industry, where Vanda Pharmaceuticals, another company in the same sector, has also shown a 1% increase in its stock price recently [4] - Vanda's consensus EPS estimate remains unchanged at -$0.34, representing a 325% decline from the previous year [5]